Skip to main content
. 2020 Sep 17;5(18):e137646. doi: 10.1172/jci.insight.137646

Figure 5. Effect on BW and organ size by treatment with TRPV4 antagonist RN 1734.

Figure 5

(A–C) BWs (A), kidney weights (B) (combined left and right) expressed as a function of BW, and wet, intact brain weights (C) expressed as a function of BW collected at P15 for all groups. WT, vehicle (n = 11); WT, RN 1734 (n = 12); Het, vehicle (n = 14); Het, RN 1734 (n = 11); Hom, vehicle (n = 11); Hom, RN 1734 (n = 12). All data shown are the mean ± SEM for each group. Significance values were determined by 2-way ANOVA test in Prism using genotype and treatment as variables. Het, heterozygous; Hom, homozygous/hydrocephalic; vehicle = DMSO/saline daily i.p. injection; RN 1734, RN 1734, TRPV4 antagonist; 4 mg/kg BW i.p. daily injection